ArticleCureus2026
Evaluation of Radioiodine (I-131) Therapy Success in Different Etiological Forms of Hyperthyroidism and Analysis of Response According to Administered Dose.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadioactive iodine (I-131) has been used for decades in the treatment of hyperthyroidism. However, the final outcome depends not only on the underlying etiology but also, to a large extent, on the initial administered activity.
objectiveThe aim of this study was to determine the success rates of radioiodine therapy in Graves' disease, toxic multinodular goiter (Plummer's disease), and toxic adenoma, and to precisely assess the impact of different I-131 activities on the risk of treatment failure.
methodsThe study included 146 patients with a clearly established etiology of hyperthyroidism. Each patient received one of four fixed activities: 10 mCi, 15 mCi, 20 mCi, or 25 mCi. Treatment outcome was evaluated six months after therapy using multinomial logistic regression (reference categories: 25 mCi dose and toxic adenoma).
resultsThe overall cure rate was 80.82%. In patients with Graves' disease, success was achieved in 78.38% of cases, with the majority developing hypothyroidism. The effect of dose was highly significant: an activity of 15 mCi increased the odds of persistent hyperthyroidism 57-fold (p < 0.05), while 10 mCi increased it 1,491-fold (p < 0.01) compared to 25 mCi. Patients with Plummer's disease had 18.36 times higher risk, and those with Graves' disease had 6.09 times higher risk of treatment failure compared to toxic adenoma (p = 0.11 and p = 0.29).
conclusionDoses below 20 mCi, particularly 10 mCi, are associated with unacceptably high failure rates. Multinodular and diffuse forms of hyperthyroidism require higher ablative activities between 20 and 25 mCi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.